Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

506.74
-16.0700-3.07%
Post-market: 510.003.26+0.64%18:49 EDT
Volume:1.19M
Turnover:607.47M
Market Cap:128.57B
PE:29.49
High:523.52
Open:522.39
Low:505.27
Close:522.81
52wk High:560.25
52wk Low:392.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:1.37
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.35
PE(LYR):33.08

Loading ...

Vortex Energy Expands Saskatchewan Portfolio with Meadows Project Acquisition

TIPRANKS
·
53 mins ago

Vertex adds AI-focused independent director to board

TIPRANKS
·
1 hour ago

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
2 hours ago

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
3 hours ago

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know

TradingKey
·
3 hours ago

Movement Alert|Vertex Pharmaceuticals Declines 3.03% in Regular Trading, Trading at $506.63

Market Focus
·
3 hours ago

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
4 hours ago

Vertex appoints Saha to Board of Directors

TIPRANKS
·
Yesterday

Press Release: Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors

Dow Jones
·
Yesterday

Vertex Pharmaceuticals Price Target Raised to $615.00/Share from $585.00 by UBS

Dow Jones
·
Sep 29

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating

MT Newswires Live
·
Sep 28

Vertex Minerals Sets October General Meeting for Shareholders

TIPRANKS
·
Sep 25

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 25

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated

TIPRANKS
·
Sep 23

Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633

THOMSON REUTERS
·
Sep 23